Overview: HLA-DR4 Typing TestIntroduction: The HLA-DR4 Typing Test detects HLA-DR4 antigen to assess rheumatoid arthritis or transplant risk, causing joint pain. Following 2023 ASHI guidelines, it uses PCR for high specificity, supporting transplant screening. This test is critical for guiding transplant decisions, evaluating rheumatoid arthritis risk, and improving outcomes in molecular pathology for patients with suspected autoimmune diseases or undergoing transplantation.
Other Names: HLA-DR4 Assay, HLA-DR4 Antigen Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: HLA typing began in the 1960s with transplant immunology. PCR-based HLA-DR4 typing improved in the 2000s, enhancing rheumatoid arthritis and transplant assessment.
Purpose: Assesses HLA-DR4 for rheumatoid arthritis or transplant compatibility, guides treatment or organ matching, and evaluates risk in patients with joint pain.
Test Parameters: 1. HLA-DR4 Antigen
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report history of joint pain, autoimmune diseases, or transplants.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document joint pain, autoimmune diseases, transplants, or family history of HLA-related conditions. Include current medications and prior transplant history.
Consent: Written consent required, detailing the tests purpose, compatibility or rheumatoid arthritis implications, and potential need for treatment or transplant planning.
Procedural Considerations: Uses PCR to detect HLA-DR4 antigen. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often for rheumatoid arthritis or transplant assessment.
Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Low DNA quality may impact typing accuracy.
Clinical Significance: Positive HLA-DR4 indicates rheumatoid arthritis risk or transplant compatibility, guiding treatment or transplant decisions. Negative results may require alternative HLA typing.
Specialist Consultation: Consult a rheumatologist or transplant immunologist for result interpretation and planning.
Additional Supporting Tests: Rheumatoid factor, anti-CCP antibodies, or antibody screening to assess rheumatoid arthritis or transplant compatibility.
Test Limitations: Limited to HLA-DR4; other HLA loci may need testing. Clinical correlation is needed for rheumatoid arthritis diagnosis.
References: ASHI HLA Guidelines, 2023; Arthritis & Rheumatology, Gregersen PK, 2022.
